Does PALBOCICLIB Cause Product dose omission issue? 2,143 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,143 reports of Product dose omission issue have been filed in association with PALBOCICLIB (Ibrance). This represents 2.4% of all adverse event reports for PALBOCICLIB.
2,143
Reports of Product dose omission issue with PALBOCICLIB
2.4%
of all PALBOCICLIB reports
62
Deaths
266
Hospitalizations
How Dangerous Is Product dose omission issue From PALBOCICLIB?
Of the 2,143 reports, 62 (2.9%) resulted in death, 266 (12.4%) required hospitalization, and 3 (0.1%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 2,143 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which PALBOCICLIB Alternatives Have Lower Product dose omission issue Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID